, impeding mechanistic insight and development of therapeutic strategies. Here, we report the identification of variants in ROBO4 (which encodes a factor known to contribute to endothelial performance) that segregate with disease in two families. Targeted sequencing of ROBO4 showed enrichment for rare variants in BAV/AscAA probands compared with controls.
. BAV/AscAA shows autosomal dominant inheritance with incomplete penetrance and male predominance. Causative gene mutations (for example, NOTCH1, SMAD6) are known for ≤1% of nonsyndromic BAV cases with and without AscAA [5] [6] [7] [8] , impeding mechanistic insight and development of therapeutic strategies. Here, we report the identification of variants in ROBO4 (which encodes a factor known to contribute to endothelial performance) that segregate with disease in two families. Targeted sequencing of ROBO4 showed enrichment for rare variants in BAV/AscAA probands compared with controls.
Targeted silencing of ROBO4 or mutant ROBO4 expression in endothelial cell lines results in impaired barrier function and a synthetic repertoire suggestive of endothelial-to-mesenchymal transition. This is consistent with BAV/AscAA-associated findings in patients and in animal models deficient for ROBO4. These data identify a novel endothelial etiology for this common human disease phenotype.
In kindreds segregating bicuspid aortic valve with ascending aortic aneurysm (BAV/AscAA), there is often wide variation in cardiovascular manifestations between affected individuals, including complete non-penetrance (skewed towards females), isolated BAV, isolated AscAA, and variable location of the site of ascending aortic dilatation, including isolated aortic root aneurysm (AoRA;
Letters NATuRe GeNeTiCs at the sinuses of Valsalva) or more distal ascending aortic aneurysm (DAscAA; collectively AscAA) [9] [10] [11] [12] . This observation suggests that BAV and AscAA are both variably penetrant primary manifestations of the same underlying gene defect (or defects). Although enrichment for BAV can be seen in syndromic presentations of thoracic aortic aneurysm (for example, Loeys-Dietz syndrome caused by mutations in genes encoding primary effectors of the transforming growth factor-β (TGFβ ) signaling pathway), isolated DAscAA is exceedingly rare in these conditions, suggesting a mechanistic distinction for nonsyndromic BAV/AscAA [13] [14] [15] . The genetic etiology and molecular pathogenesis of nonsyndromic BAV/AscAA remains largely elusive despite intensive effort. Probable obstacles to progress include extreme locus heterogeneity and the confounding influence of incomplete penetrance, sex bias, and environmental and/or genetic modification of disease onset and severity. In this study, we sought to identify genes responsible for nonsyndromic BAV/AscAA using whole-exome sequencing (WES) and a familial segregation approach.
A total of nine patient families (Fig. 1a,c and Supplementary  Fig. 1 ), 286 individual probands, and 193 unrelated controls without structural heart disease were enrolled in our WES initiative. In one large family (family 1), eight individuals showed AoRA with or without DAscAA, and two had associated BAV (Fig. 1a) .
Initial sequencing of a panel of genes implicated in familial thoracic aortic aneurysm (ACTA2, FBN1, MYH11, MYLK, SMAD3, TGFBR1, TGFBR2) [16] [17] [18] [19] [20] [21] identified no mutations. WES in five affected individuals of family 1 identified a novel heterozygous mutation at the splice acceptor site of ROBO4 exon 13 (g.124757628C> A, c.2056+ 1G> T, denoting the variant position in genomic DNA and complementary DNA, respectively; NC_000011.9 and NM_019055.5) (Fig. 1a and Supplementary Fig. 2a) . We confirmed that all eight affected family members carried the mutation.
Interestingly, seven of eight affected individuals were male, including both with BAV. Two clinically unaffected female family members were heterozygous for the ROBO4 splice-site mutation. Pathology from one family member with BAV showed valve thickening in association with a pronounced fibroproliferative process ( Supplementary Fig. 2b ). Amplification and sequencing of complementary DNA derived from patient and control fibroblasts showed that the splice-site mutation results in the skipping of the 108-bp encoding exon 13 of ROBO4, resulting in an in-frame transcript encoding a protein isoform missing 36 amino acids from the intracellular domain (Fig. 1b) . In family 2, WES identified a heterozygous ROBO4 missense variant (c.190C> T, p.Arg64Cys) in a woman with atrial septal defect (ASD) and aortic valve stenosis (AVS) that required surgery, and her son with ASD, BAV, and significant AVS ( Fig. 1c and Supplementary Fig. 2c ). This variant is exceedingly rare (Exome Aggregagion Consortium (ExAC) frequency: 19 out of 98,998), predicted to be deleterious by Polymorphism Phenotyping (Polyphen) and SIFT (Sorting Intolerant From Tolerant v.6.2.1), and predicted to be among the top 1% of most deleterious substitutions possible in the human genome by the Combined Annotation Dependent Depletion (CADD v1.0) algorithm (score 21.6). The mutation substitutes an evolutionarily conserved residue in the immunoglobulin-like C2-type 1 extracellular domain of ROBO4. Of the additional 286 individual probands evaluated, four variants (p.Ala95Thr, p.Thr232Met, p.His411Gln, and p.Arg568Ter) met our a priori filter, restricting our focus to exceedingly rare (minor allele frequency (MAF) < 0.01%) or rare and predicted highly deleterious (MAF < 0.1% and CADD > 20) variants ( Fig. 1d and Table 1 ). All four variants were confirmed by Sanger sequencing.
We then sequenced an additional 441 probands with BAV/ AscAA and 183 unrelated controls, with echocardiogram-confirmed absence of structural cardiovascular disease, for ROBO4 
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NATuRe GeNeTiCs variants using the Haloplex target enrichment system (99.47% of ROBO4 base positions with ≥ 10× coverage in 90% of samples). Seven additional BAV/AscAA probands harbored heterozygous ROBO4 variants that fulfilled filtering criteria, including five missense variants and one frameshift mutation ( Fig. 1d and Table 1; see  Supplementary Table 1 for corresponding clinical data). The missense variants observed in the targeted sequencing cohort include an independent example of the p.Arg64Cys variant observed in family 2. In addition, we observed an exceedingly rare variant (p.Asp622His; ExAC frequency, 4 out of 110,004) predicted to be highly deleterious (CADD score 21.3) in two unrelated probands recruited at distant sites. Collectively, among familial and individual probands (WES and targeted sequencing), 13 out of 736 (1.77%) had a ROBO4 variant that passed a priori filtering constraints, while one rare (absent from ExAC) missense variant was observed among 376 rigorously phenotyped controls (two-tailed Fisher's exact test, P = 0.0432). Consistent with BAV overall, the majority of BAV/AscAA probands identified with putative pathogenic ROBO4 variants were male (Supplementary Table 1 ). The mechanistic basis for this observation is unknown.
We next sought to elucidate the functional consequence of mutant ROBO4 alleles. Histologic and immunofluorescence analyses were performed on resected ascending aortic aneurysm tissue from patient 1.II:1 and compared to normal ascending aorta derived from an age-and sex-matched control individual. ROBO4 was strongly expressed in endothelial cells in control aorta, as evidenced by co-localization with platelet endothelial cell adhesion molecule 1 (CD31) but was diminished in the endothelium in the BAV/AscAA sample (Fig. 2a,c) .
Both control and diseased aorta showed expression of ROBO4 in the intima in the absence of co-expression of α -smooth muscle actin (α SMA, encoded by ACTA2), a vascular smooth muscle cell mesenchymal marker (Fig. 2b) . However, the aneurysm tissue uniquely showed infiltration of ROBO4 + cells into the aortic media with co-staining for α -SMA. Given ROBO4 expression in the endothelial lining of the vasculature 22 and a described role in establishing endothelial barrier function 23, 24 , we hypothesized enhanced vascular permeability in the ascending aorta of patients with BAV/AscAA. In keeping with this hypothesis, immunostaining for albumin was restricted to the endothelial surface in control aorta, but substantial penetration into the aortic intima was observed in patient tissue (Fig. 2d) . Histological analyses showed a strong fibroproliferative response in the intima and superficial medial layer of patient aorta, as evidenced by increased cellularity and the accumulation of collagen upon Masson's trichrome staining. Furthermore, decreased elastin content, and fragmentation and disarray of elastic fibers in the superficial media were observed upon Verhoeff-Van Gieson (VVG) staining (Fig. 2e) . Collectively, these data suggest that ROBO4 variants disrupt endothelial cellular performance and barrier function, contributing to pathological remodeling of the aortic media.
To further address the impact of ROBO4 alterations on endothelial cell performance, cultured human aortic endothelial cells (HAECs) were transiently transfected with short interfering RNA (siRNA) against ROBO4 or with constructs overexpressing either wild-type ROBO4, a form lacking exon 13, or a form with the p.Arg64Cys missense variant. Furthermore, to assess the individual performance of the ROBO4 variant seen in family 1, HAECs with silenced endogenous ROBO4 expression (siRNA targeting sequence in exon 13) were transfected with the expression construct lacking exon 13 (termed SS-Alone). The expression of wild-type and mutant ROBO4 mRNA was assessed by quantitative RT-PCR (PCR with reverse transcription) (Fig. 3a) .
ROBO4 silencing or expression of ROBO4 variants resulted in loss of endothelial barrier function in a dextran permeability assay (Fig. 3b) . Loss of barrier function was associated with downregulation of expression of TJP1 and VE-cadherin mRNA and protein, indicative of loss of tight-and adherens-junction integrity, respectively (Fig. 3c) . Other phenotypes that were seen included induction of expression of α -SMA and Snail1 mRNA, and cellular elongation and invasion. Assessment of expression of prototypical target genes suggested a modest decline in bone morphogenetic protein (BMP) and Notch activity without altered TGFβ responses upon ROBO4 IgL1, immunoglobulin-like 1. FN1 and FN2, fibronectin type III-like domain 1 and 2. For the fusion patterns, R-L, right-left coronary cusp fusion; L-R, left-right coronary cusp fusion; R-N, right-noncoronary cusp fusion; N/A, no data available.
NATuRe GeNeTiCs silencing ( Supplementary Fig. 3 ). Together, these results suggest that reduction or structural disruption of ROBO4 compromises endothelial identity and performance, as well as its capacity to suppress transition to a mesenchymal invasive character and synthetic repertoire. These data suggest that loss of function (by functional haploinsufficiency or the antimorphic effects of overexpressed mutant protein) is the relevant pathogenic mechanism. The distribution of missense variants along the full length of the gene and protein argues against particular relevance for any domain-specific function such as homo-or heterodimerization, interaction with other binding partners, or recruitment of SLIT ligands. ROBO1, ROBO2, SLIT2, and SLIT3 are expressed in or adjacent to the endocardial cushions and heart valves during mouse development 25 . Targeted homozygous disruption of both Robo1 and Robo2 or Slit3 resulted in highly penetrant septal defects with variably penetrant valve anomalies, including BAV. We observed that mouse ROBO4 was expressed in the endocardial layer of the cushions and delamination zones at embryonic day 11.5 (E11.5; Supplementary Supplementary Fig. 4a,b) . At 5 weeks after birth, ROBO4 was localized to the endothelial layer of the ascending aorta and persisted throughout postnatal development ( Supplementary Fig. 4b ). In normal adult human ascending aorta, ROBO4 is expressed in endothelial and intimal cells (Fig. 2 and Supplementary Fig. 4c ). Similarly, robo4 is known to be expressed in the developing vasculature of zebrafish 26 . Together, these results confirm the expression of ROBO4 in cells relevant to the pathogenesis of BAV/AscAA.
Next, we established a mutant zebrafish (Danio rerio) line harboring a 7-bp deletion in exon 6 of robo4 (robo4 ∆7 ; Supplementary  Fig. 5a ). This frameshift mutation leads to a low steady-state abundance of robo4 mRNA due to nonsense-mediated mRNA decay ( Supplementary Fig. 5b ). We observed no gross defect in robo4-mutant larvae ( Supplementary Fig. 6 ). Among the adult mutant zebrafish assayed by echocardiography, , co-siRNA (control short interfering RNA), OE-WT (overexpression of ROBO4 wild-type plasmid), siRNA (global ROBO4 knockdown), siRNA-Ex13 (ROBO4 knockdown through targeting of exon 13), OE-SS (overexpression of ROBO4 cDNA plasmid without exon 13), SS-alone (overexpression of ROBO4 cDNA plasmid without exon 13 plus silencing of endogenous ROBO4 using siRNA targeting exon 13), or OE-R64C (overexpression of ROBO4 cDNA plasmid with p.Arg64Cys). ROBO4 mRNA expression was quantified. b, HAECs were cultured to confluency, and a dextran permeability assay was used to assess the integrity of the endothelial barrier. Error bars show mean ± s.e. (n = 6). Asterisks signify significant differences using one-way ANOVA with Tukey's posthoc test (D.F. = 7, *P < 0.05, **P < 0.01). c,d, Immunofluorescence staining of tight junction protein ZO-1, VE-cadherin and DAPI (blue). TJP1 (encoding tight junction protein ZO-1) expression and CDH5 (encoding VE-cadherin) expression were analyzed via qRT-PCR. For a, c and d, error bars show mean ± s.d. (n = 6). Asterisks signify significant differences using a one-way ANOVA with Tukey's post-hoc test (D.F. = 7, *P < 0.05, **P < 0.01).
disruption of robo4 in zebrafish perturbs outflow tract function. Although overt vascular enlargement was not observed, it is unclear whether the zebrafish system is ideal for assessing this specific aspect of the phenotype given substantive anatomic and physiologic differences from mammals and the limited duration of observation. We next examined the effect of ROBO4 loss of function in mice using the Robo4 tm1Lex model, which lacks exons 1 to 3. Robo4 transcripts were not detected in homozygous Robo4 tm1Lex/tm1Lex mice via qRT-PCR ( Supplementary Fig. 7a ). None of the evaluated heterozygotes (Robo4 tm1Lex/+ ) presented with any structural or functional abnormality. Homozygous Robo4 tm1Lex/tm1Lex knockout mice exhibited a complex cardiovascular phenotype that includes a combination of aortic valve thickening with or without BAV, aortic valve stenosis and/or regurgitation and/or AscAA. In general, these phenotypes were observed with low penetrance and male predominance. Overall, at 20 weeks of age, 5 out of 28 (17.9%) male and 2 out of 18 (11.1%) female Robo4 tm1Lex/tm1Lex mice were affected compared to 0 out of 22 (0%) and 0 out of 19 (0%) Robo4 +/+ males and females, respectively (P < 0.01; Fig. 4 ). In addition, one mouse with aortic regurgitation presented with a quadricuspid aortic valve ( Supplementary Fig. 7b ).
We next sought to evaluate the in vivo consequence of the splice mutation (g.124757628C> A, c.2056+ 1G> T) that we had observed in family 1 by establishing a knock-in mouse line harboring a mutation (Robo4 Skip13 ) at the splice donor site in intron 13 of Robo4 (c.2089+ 1G> T) (Supplementary Fig. 8a ). Sanger sequencing of cDNA amplicons spanning exons 11-14, using mRNA derived from ) mice 20 weeks after birth. Aortic dilatation was defined as a Z-score greater than two when compared to wild-type male mice by echocardiography. Statistical differences were assessed using one-tailed Fisher's exact test (n = 112 total male and female mice, P < 0.05 was considered statistically significant). Aortic valve (AoV) defect: abnormal aortic valve morphology, including BAV, distal commissure fusion, leaflet thickening, or quadricuspid aortic valve among mutant mice with flow abnormalities by echocardiogram. Comparison is made to a representative sample of wild-type mice. Pure BAV: pure bicommissural aortic valve that was definitively evident by gross inspection. N/A, not assessed. See Supplementary Table 3 for raw data. b, Representative parasternal long axis and pulsed-wave Doppler images. Red arrows indicate a dilated segment of the ascending aorta. The yellow arrow shows increased velocity of outflow across the aortic valve during systole, while the orange arrow shows regurgitant flow during diastole in a Robo4 tm1Lex/tm1Lex mouse (similar patterns were seen in the seven affected mice). c, Gross and histological examination of the aortic valve. Numbers refer to individual commissures.
NATuRe GeNeTiCs the ascending aorta of targeted animals, showed either in-frame skipping of exon 13 (exons 12/14) or inclusion of exon 13 with activation of a cryptic splice donor in intron 13 ( Supplementary Fig.  8b,c) . Using TaqMan probes specific to individual exons or splice junctions, we determined that wild-type mice show 100% normal splicing (exons 12/13/14). Representation of exons 12/13/14, exons 12/13 + intron 13, and exons 12/14 transcripts was approximately 50%, 28%, and 22%, or approximately 0%, 55%, and 45% in Robo4 +/Skip13 or Robo4 Skip13/Skip13 animals, respectively ( Supplementary   Fig. 8d ). We conclude that the Robo4 Skip13 mutation alters premRNA splicing with significant representation of mature mRNA lacking exon 13.
Like the knockout mice, Robo4 Skip13 mice presented with an incompletely penetrant complex cardiovascular phenotype that included aortic valve defects and aortic valve dysfunction and AscAA. At 20 weeks, 1 out of 31 (3.2%) Robo4
Skip13/+ and 4 out of 35 (11.4%) Robo4
Skip13/Skip13 male mice were affected compared to 0 out of 18 Robo4 +/+ mice (P < 0.05; Fig. 5 ). ) mice were aged to 20 weeks and the cardiovascular phenotype was determined. Aortic dilatation was defined as a Z-score greater than two when compared to wild-type male mice by echocardiography. Significant differences were assessed using a one-tailed Fisher's exact test (n = 106 total male mice, P < 0.05 was considered statistically significant). AoV defect: Abnormal aortic valve morphology including BAV, distal commissure fusion, leaflet thickening, or quadricuspid aortic valve among mutant mice with flow abnormalities by echocardiogram. Comparison is made to a representative sample of wild-type mice. Pure BAV: pure bicommissural aortic valve that was definitively evident by gross inspection. See Supplementary Table 4 for raw data. b, Representative parasternal long-axis and pulsed-wave Doppler images. Red arrows indicate a dilated segment of the aortic root. The yellow arrow shows increased velocity of outflow across the aortic valve during systole while the orange arrow shows regurgitant flow during diastole in a Robo4
Skip13 mouse (similar patterns were seen in the five affected mice). c, Gross and histological examination of the aortic valve. Numbers refer to individual commissures.
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We demonstrate that heterozygous mutations in ROBO4 are sufficient to cause a nonsyndromic presentation of BAV/AscAA. The distribution of expression of ROBO4 in both the developing valve and the ascending aorta is consistent with the view that BAV and aortic aneurysm present as independent primary manifestations of the same underlying gene defect, a concept further supported by the presence of either BAV/AscAA, isolated BAV, or isolated AscAA in family members segregating the same ROBO4 variant. This study highlights many obstacles in the elucidation of etiologies for BAV/AscAA. Such obstacles include a relatively low frequency for involvement of any specific disease gene (also evident for NOTCH1 and SMAD6), apparent extreme locus heterogeneity, functional redundancy within relevant pathways, low penetrance with sex bias, and the lack of signatures for loss-of-function intolerance that is likely to be related to both the penetrance issue and to later onset of the phenotype and hence minimal, if any, impact on reproductive fitness. This study focuses attention on endothelial cell biology in BAV/AscAA, with impairment of barrier function and/or dysregulation of mesenchymal transition potentially contributing to disease expression. Prior work has suggested that abnormal plasma protein (for example plasminogen) trafficking in the vessel wall might contribute to aneurysm phenotypes by enhancing proteolytic activity, TGFβ bioavailability, or other mechanisms 27, 28 . Other studies have suggested an association between BAV/AscAA and an endothelialto-mesenchymal (EnMT)-like phenotype in the aortic wall 29 and decreased mesenchymal potential of endothelial cells derived from such patients 30 , but neither study had defined the etiology or mechanism for these findings. Although our study of isolated endothelial cells did not identify a predominant pathway driving apparent EnMT in the context of ROBO4 deficiency, a confluence of data provides further incentive to interrogate altered mesenchymal transition as a pathogenic driver and a therapeutic target in BAV/AscAA using model systems that mimic the anatomic and physiologic complexity of the left ventricular outflow tract and ascending aorta.
URLs. Circularity in ImageJ, https://imagej.nih.gov/ij/plugins/circularity.html; CRISPR design tool, http://crispr.technology.
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NATuRe GeNeTiCs in the experimental design and interpretation of the data. C.P., N.S., H.Ling, A. A.K., I.L., E.C., A.V., H.M.B., A.-C.L., V.J.-R., H.J., A.A.S., C.L Whole-exome sequencing. Genomic DNA was extracted from peripheral blood lymphocytes using standard protocols. DNA fragmentation was performed using a Covaris S2 system, and exon capture was performed using the Agilent SureSelect 38-Mb Human All Exon Target Enrichment system. DNA sequencing was performed on an Illumina Genome Analyzer IIx instrument with using standard protocols for 75-bp paired-end runs.
Bioinformatics analysis. Reads were mapped to the human reference genome (UCSC hg19) using the Burrows-Wheeler Aligner (BWA) and a variant list created using SAMtools, which were annotated using ANNOVAR [32] [33] [34] . Local realignment and recalibration of base call quality scores was performed using the Genome Analysis Toolkit (GATK) 35, 36 . Duplicates were identified using Picard. We selected for rare variants (dbSNP, exome variant server, ExAC) and focused only on exonic non-synonymous, splice-site and insertion and/or deletion (indel) variants. Variants were viewed directly using the Integrated Genome Viewer (IGV) and excluded if reads were only present in one direction, if ambiguously mapped reads were present, or if an indel occurred within 3 bp of the end of the read 37 .
Mutation validation and Sanger sequencing of candidate genes. Bidirectional Sanger DNA sequencing assays were performed using primers designed 60-120 bp from the variants or intron-exon boundaries to confirm candidate variants or sequence candidate genes. PCR was performed using a DNA Engine Dyad thermal cycler (Bio-Rad). Phusion Flash High Fidelity PCR Master Mix was used in accordance with the manufacturer's instructions for each primer set (Thermo Scientific). Cycle sequencing was performed using the BigDye Terminator v3.1 kit and an ABI 3730xl DNA Analyzer in accordance with the manufacturer's instructions (Life Technologies). Samples were purified using the QIAquick PCR Purification kit (Qiagen).
Targeted sequencing. Enrichment for all exons of ROBO4, including ± 10 bp of adjacent intronic sequences, was performed with a custom Haloplex target enrichment kit, following instructions of the manufacturer (Agilent Technologies). Probe design covered a theoretical 99.7% of the complete target region. Pooled samples were sequenced either on a HiSeq 2500 (Illumina) with 2 × 150 bp reads or on a HiSeq 1500 (Illumina) with 2 × 100 bp reads.
Cell culture and transfection. Primary human dermal fibroblasts were derived from forearm skin biopsies from one control individual, a control cell line (ATCC), or a single proband. Cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) in the presence of antibiotics and were passaged at confluence. HAECs (Promocell, Heidelberg) were cultured in EGM2 BulletKit (Lonza, CC-3156/CC-4176) and used for experiments at P2-P4. For initial transfection experiments, cells were seeded at 60-70% confluence. ROBO4 constructs were mixed with Lipofectamine 3000 (Invitrogen), diluted in EGM2 (without antibiotics) (for constructs, see Supplementary Table 5) , and treated for 24 h. HAEC media was then replaced and allowed to culture for an additional 48 h. Transfection efficiency was measured via qRT-PCR and immunofluorescence.
RNA isolation and qRT-PCR.
For human and mouse samples, RNA extractions were performed using a Qiagen total RNA purification kit (Qiagen) and RNA was reverse transcribed to cDNA using the SuperScript III RT-PCR kit with oligo(dT) primer (Invitrogen). Real-time PCR experiments were conducted using the FAM-MGB PCR system (Applied Biosystems) on QuantStudio 7 Real-Time ABI 384 cycler, with 40 cycles per sample. Primers were normalized to 18S or GAPDH. The following pre-validated probes were used for mRNA analysis: H200219408_m1 (Robo4), Hs01551861_m1 (TJP1), Hs00901463_m1 (CDH5), Hs00426835_g1 (ACTA2), Hs00195591_m1 (SNAI1), Hs00170014_m1 (CTGF), Hs00167155_m1 (SERPINE1), Hs03676575_s1 (Id1), Hs04187239_m1 (Id2), Hs00954037_g1 (Id3), Hs01114113_m1 (Hey1), Hs00232622_m1 (Hey2), Hs03003631_g1 (18S), and Hs02758991_g1 (GAPDH) (Life Technologies). For zebrafish, RNA extracts were prepared from isolated wild-type or robo4 knockout adult hearts using RNA TRIzol (Ambion) and cDNA was synthesized using SuperScript III Reverse Transcriptase kit (ThermoFisher Scientific). Two sets of specific primers spanning the junctions of exons 9 and 10, and of exons 16 and 17 were designed (see Supplementary Table 5 ). All qRT-PCR data were obtained using the ViiA 7 Real-Time PCR System (Applied Biosystems) and SYBR Green PCR Mix (ThermoFisher).
Antibody staining. Samples were fixed in 4% paraformaldehyde overnight at 4 °C. Samples were then washed for 15 min on a rocker three times with PBS buffer, permeabilized with 0.2% Triton-X 100 (VWR International) for 10 min, and washed another three times with PBS. Samples were incubated overnight at 4 °C in a 1% BSA (Rockland Immunochemicals) blocking solution followed by another 4 °C overnight incubation with antibodies against ROBO4 (Abcam, ab103674), ROBO4 (Santa Cruz, sc-46497), CD31 (Biocare Medical, CM303A), PECAM1 (Santa Cruz, sc-1506), CDH5 (Santa Cruz, sc-28644), TJP1 (Santa Cruz, sc-8146), ACTA2 (Abcam, ab7817), or ALB (Santa Cruz, sc-46293). After three washes for 15 min with PBS, samples were exposed to Alexa Fluor 488 or 568 conjugated (Invitrogen) species-specific secondary antibodies at 1:100 in 1% BSA for 2 h at room temperature. Three more washes with PBS for 15 min were followed by incubation with either DRAQ5 (far-red) nuclear stain or DAPI (UV) nuclear stain (Enzo Life Sciences) at 1:1,000.
Permeability assay. Permeability assays were performed as described previously 38 . HAECs were utilized at or before passage six. Cells were detached using 0.05% trypsin-EDTA (Thermo Fisher Scientific), pelleted, then re-suspended in a growth medium to a concentration of 0.5-1× at 10 6 cells ml -1
. Dry collagen pre-coated porous inserts were rehydrated for 15 min in a growth medium prior to cell seeding (1.0-µ m pores, EMD Millipore). HAECs were seeded in 200 µ l of growth medium per 24-well insert. 500 µ l were added to each receiver plate well. HAECs were cultured in a tissue culture incubator at 37 °C with 5% CO 2 for 72 h to allow for a monolayer formation. Following endothelial monolayer formation, growth medium was carefully removed. This was replaced with medium containing different ROBO4 constructs (see Supplementary Table 5 ). Samples were returned to 37 °C incubation for 24 h. Afterwards, the treatment medium was carefully removed. A high molecular weight FITC-dextran solution (40 kDa) was created by 1:40 dilution in a growth medium and added at 150 µ l. Growth medium was added to each receiver plate well at 500 µ l (24-well plate). The FITC-dextran permeated the monolayers for 2 h. The inserts were removed from the receiver wells to stop permeation. The medium in the receiver wells was then mixed thoroughly and 100 µ l was removed from each well to a black 96-well opaque plate for fluorescence measurement. Permeability was quantified on a Synergy-II fluorescent plate reader (Biotek) via fluorescence at 485 nm excitation/535 nm emission wavelengths (1 s fluorescence count time). The endothelial monolayer was stained after completion of fluorescein isothiocyanate (FITC)-dextran permeability testing for subsequent confocal imaging.
Cell morphology assay. Cell shape was calculated as described previously 39 , using Circularity in ImageJ (see URLs). Cell shape changes were tracked automatically over subsequent images, and quantified as a cell circularity index (CI = 4 × Pi × (area/perimeter 2 )). A circularity value of 1.0 indicates a perfect circle. As the value approaches 0.0, it indicates an increasingly elongated polygon.
Endothelial aggregate invasion assay. For invasion assays, cells were re-suspended in culture media and allowed to aggregate overnight in hanging drop culture (20 μ l; 20,000 cells). The aggregates were then placed on the surface of neutralized type I collagen hydrogels (1.5 mg ml −1 ), as described previously 40 and allowed to adhere for 2 h before adding treatments. Cultures were then transfected for 24 h with the ROBO4 constructs (see Supplementary Table 5 ) and maintained for another 72 h. Cell invasion was quantified manually at a 50-μ m depth into the gel and normalized to control.
Proliferation assay. 5-Bromo-2′ -deoxyuridine (BrdU) incorporation was used to detect proliferating cells, as described previously 41 . Cultures were transfected for 24 h with the ROBO4 constructs (see Supplementary Table 5 ). BrdU labeling reagent (Invitrogen) was added to the culture media for 12 h after treatment. After 24 h, cells were fixed and targeted with a monoclonal Anti-BrdU Alexa Fluor 488 conjugate (PRB-1, Invitrogen) while total DNA was counterstained using a DAPI dye. Positive fluorescent areas for each cell were measured using ImageJ and normalized by cell nuclei. Scratch assay. Migratory ability was tested as described previously 42 . In brief, cells were cultured to confluency and then transfected for 24 h with the ROBO4 constructs. A scratch was then introduced using a 200-μ l pipette tip. The cells were then incubated at 37 °C and observed at 24 h. Differences in filling in the scratch were observed to establish the capability of cellular migration.
Zebrafish and mouse maintenance. Adult AB and robo4 ∆7 mutant zebrafish lines were maintained in system water according to standard methods 43 . Mice were housed in the Johns Hopkins University School of Medicine East Baltimore campus. All strains were maintained on a mixed C57BL/6J and F129/SVE background. All upkeep and experimental procedures for zebrafish and mice were in accordance with the ethical guidelines set by the Johns Hopkins Institutional Animal Care and Use Committee.
Generation of a robo4 knockout zebrafish line by CRISPR-Cas9. We designed a single guide RNA (gRNA, see sequences in Supplementary Table 6 ) to target the robo4 gene (gRNA robo4 ), using ZiFit 44, 45 . Cas9 RNA was synthesized from linearized pCS2-nls-zCas9-nls (AddGene, no. 47929) 46 . We injected 100 ng nl −1 of gRNA and 300 ng of Cas9 in a 5-µ l solution into one-cell wild-type (AB) zebrafish embryos and raised them to maturity (F 0 ). To identify fish capable of germline transmission, we crossed F 0 males with AB females. Germline transmission was confirmed by Surveyor Assay (IDT) in pooled F 1 embryos (n = 50) followed by Sanger sequencing. Heterozygous F 1 adults with the same 7-bp deletion were inbred to establish the line (robo4 jh176 ). All subsequent generations were genotyped using primer set F2 and R2 (see Supplementary Table 6 ).
Robo4 knockout mice and generation of Robo4 knock-in mice. Robo4 tm1Lex knockout mice were purchased through the mutant mouse resource and research centers supported by the National Institutes of Health (NIH) (MGI:5007309, Lexicon Pharmaceuticals). The mice were bred in a heterozygous state on a mixed background of 129S5/SvEvBrd and C57BL6/J. To generate Robo4 knock-in mice, we targeted the Robo4 locus using CRISPR-Cas9 (clustered, regularly interspaced palindromic repeat-CRISPR-associated protein 9). Two single-guide RNA (sgRNA) sequences (see Supplementary Table 7) were designed to target exon 13 of Robo4 (NC_000074.5) using a gRNA CRISPR design tool (see URLs) 47 . The gRNAs were not predicted to have any off-target effects. These oligonucleotides were cloned into a pX459 plasmid 48 (Addgene, no. 48139) and appended with a T7 promoter. The sgRNA was transcribed in vitro. The homology directed repair (HDR) template was purchased as a 4-nmol Ultramer (IDT, see Supplementary Table 6 ). The sgRNA, Cas9 (TriLink BioTechnologies), and HDR were co-injected into C57BL/6J zygotes (Johns Hopkins University Transgenic Core). Pups (n = 41) were screened for locus editing by Sanger sequencing (IDT, see Supplementary Table 7 ). Mice (Robo4
Skip13
) were subsequently genotyped by Sanger sequencing (271-bp amplicon). Mice were then crossed to a mixed background (129S5/SvEvBrd and C57BL6).
Zebrafish and mouse echocardiography. For zebrafish, we used the Vevo 2100 Imaging System equipped with a 70-MHz ultrasound transducer (VisualSonics). The zebrafish were anesthetized by placing the fish into a plastic cup filled with 100 ml of 168 μ g ml −1 MS-222 (Tricaine methanesulfonate, Fluka Analytical). For mice, echocardiograms were undertaken on awake, unsedated mice using the Vevo 2100 Imaging System (VisualSonics) and a 40-MHz transducer. Echocardiographic recordings for the mice were taken using a parasternal long-axis or sagittal short-axis view; three independent measurements of the maximal internal dimension at the sinus of Valsalva and ascending aorta were made and averaged. All data acquisition and measurements for mice and zebrafish were performed blinded to the genotype. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Randomization In vitro samples were allocated based on experimental conditions. Organisms were allocated based on genotype and sex. Human patients were allocated based on phenotype.
Blinding
Echocardiographic measurements and phenotypic assessments were all performed by observers blinded to genotype. Genotype was not revealed until all analyses were complete.
Reporting for specific materials, systems and methods 
Validation
All antibodies were commercially available and used for their intended application (assay and species). All antibodies identified epitopes with the expected subcellular localization and validated in part by correlating with mRNA levels in cell culture experiments.
Eukaryotic cell lines Policy information about cell lines
Cell line source(s)
PromoCell-Human Aortic Endothelial Cells (HAoEC)-C-12271
